Andros Pharmaceuticals Co (ROCO:6917) Cash-to-Debt : 16.32 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Andros Pharmaceuticals Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 16.32.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Andros Pharmaceuticals Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Andros Pharmaceuticals Co's Cash-to-Debt or its related term are showing as below:

ROCO:6917' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.96 Med: 2.93 Max: 16.32
Current: 16.32

During the past 5 years, Andros Pharmaceuticals Co's highest Cash to Debt Ratio was 16.32. The lowest was 1.96. And the median was 2.93.

ROCO:6917's Cash-to-Debt is ranked better than
62.48% of 1527 companies
in the Biotechnology industry
Industry Median: 6.24 vs ROCO:6917: 16.32

Andros Pharmaceuticals Co Cash-to-Debt Historical Data

The historical data trend for Andros Pharmaceuticals Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Andros Pharmaceuticals Co Cash-to-Debt Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

2.93

2.39

1.96

8.15

16.32

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			1.96	5.38	8.15	7.32	16.32

Competitive Comparison of Andros Pharmaceuticals Co's Cash-to-Debt

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Cash-to-Debt falls into.

Andros Pharmaceuticals Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Andros Pharmaceuticals Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	442.609	/	(5.097	+	22.024)
	=	16.32

Andros Pharmaceuticals Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	442.609	/	(5.097	+	22.024)
	=	16.32

Andros Pharmaceuticals Co (ROCO:6917) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Andros Pharmaceuticals Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co (ROCO:6917) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co (ROCO:6917) Headlines

No Headlines